Department of Women's Health, Dell Medical School, University of Texas at Austin, and the Comprehensive Fetal Care Center, Dell Children's Medical Center, Austin, Texas.

Corresponding author: Kenneth J. Moise, Jr, MD, Department Health Dell Medical School, University of Texas at Austin, Austin, TX; email: [email protected].

Financial Disclosure Dr. Moise disclosed the following: funding from Janssen Pharmaceuticals, Inc., paid on his behalf to Dell Medical School at the University of Texas at Austin for a clinical trial on a monoclonal antibody for the treatment of hemolytic disease of the fetus and newborn; royalty funding from UpToDate, Inc., for authorship on various chapters; consulting fees from Health Management Associates, Inc., for consultation on the formation of fetal centers; consulting fees from BillionToOne, Inc., paid on his behalf to Dell Medical School at the University of Texas at Austin; and honoraria from GLC Healthcare, Inc., for podcast content on hemolytic disease of the fetus/newborn. Lastly, Dr. Moise serves as a non-paid consultant for Immunology for Janssen Pharmaceuticals, Inc.

The author has confirmed compliance with the journal's requirements for authorship.

Peer reviews are available at https://links.lww.com/AOG/D88.